Eyegate Pharmaceuticals Stock Price - EYEG

0.00 (0.00%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Eyegate Pharmaceuticals Inc EYEG NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.59 8.93% 7.20 6.6434 7.93 6.68 6.61 00:00:07
Bid Price Ask Price Spread Spread % News
6.50 7.90 1.40 17.72% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
732 136,404 $ 7.26 $ 990,524 76,831 0.15 - 13.4995
Last Trade Time Type Quantity Stock Price Currency
19:33:37 formt 172 $ 7.20 USD

Eyegate Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 32.75M 4.55M $ -10.81M -4.93 - 3.59M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Eyegate Pharmaceuticals News

Loading Messages....

Latest EYEG Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical EYEG Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week6.547.936.246.7136,4600.6610.09%
1 Month5.757.935.606.3351,2951.4525.22%
3 Months7.4613.49955.608.19113,021-0.26-3.49%
6 Months0.15513.49950.156.79208,7757.054,545.16%
1 Year0.4313.49950.152.59296,1446.771,574.42%
3 Years2.5013.49950.151.35537,2604.70188.0%
5 Years7.0513.49950.151.51402,9170.152.13%

Eyegate Pharmaceuticals Description

Eyegate Pharmaceuticals Inc is a US-based clinical-stage specialty pharmaceutical company. It focuses on developing and commercializing products for treating diseases and disorders of the eye. The company's lead product EGP-437 incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate, that is delivered into the ocular tissues through proprietary drug delivery system, the EyeGate II Delivery System. It mainly develops EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients and uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and ciliary body.

Your Recent History
Eyegate Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.